May 7, 2013

Pittsfield, MA – Nuclea Biotechnologies, Inc. today announced that it has raised $4.2 million in its Series D funding round.  The company is planning to close the $5 million dollar Series D offering by May 31st. The new funds will be used for the commercialization of Nuclea’s Fatty Acid Synthase (FAS) assays along with other clinical assays, including the in vitro diagnostic her-2/neu ELISA assay which forged Nuclea’s recent partnership with WILEX Inc.

Since its creation in 2005, Nuclea has raised at total of $40.3 million. The Pittsfield-based company is focused on the development, clinical validation and commercialization of novel diagnostic and prognostic assays. The new funds will be used for marketing, strengthening strategic partnerships, and building hospital relationships.

"This is a new era for Nuclea Biotechnologies," said Patrick Muraca, President & CEO of Nuclea. "Now, we move from the development stage into the commercialization stage. This is a key milestone in the trajectory of Nuclea’s growth; all of our previous successes were working towards this transition into the commercialization of our diagnostic assays."

"This round of financing puts us in a good position to capitalize on the Company’s commercial opportunities," added Nuclea CFO Robert Pierce. "We expect commercial sales to begin in the second quarter from our partnership with WILEX Inc., to be followed soon after by sales from our own lab developed tests."

Nuclea Biotechnologies, Inc. -- is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.